Emmanuel Sleiman’s Post

Today we are excited to announce our collaboration with NMDP BioTherapies to advance our TCR T-cell therapy into human trials. NMDP BioTherapies will provide healthy donor materials for our upcoming Phase 1/2a trial (TCX-101) of our first-in-human product (BSB-1001). The Phase 1/2a trial will evaluate BSB-1001 in combination with allogeneic stem cell transplant in patients with high-risk leukemias, including relapsed or refractory acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and myeloid dysplastic syndrome (MDS). Learn more here: https://lnkd.in/g4C5kxdy

The optimization of conventional treatments for pediatric acute lymphoblastic leukemia (ALL) and pediatric acute myeloid leukemia (AML) has reached its limit, with almost 90% of children with ALL and more than 70% of those with AML being cured with multiagent chemotherapy protocols, together with, in some selected subsets of patients, allogeneic hematopoietic stem cell transplantation. The intensity of chemo/radiotherapy cannot be increased further in children with either ALL or AML. Read here the introduction to a new review series: all we need to know about the current use and future prospective applications of different types of immunotherapies in pediatric patients with ALL or AML. https://lnkd.in/e6EbwiaX

Patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) with spliceosome mutations who undergo allogeneic hematopoietic cell transplantation (allo-HCT) have significantly better overall survival (OS) and lower non-relapse mortality (NRM) compared to those without these mutations, according to a study. Read the full article here ⤵️ #Oncology #StemCellTransplant #Leukemia

📢Update in Follicular Lymphoma Treatment! The EBMT and ASTCT have released updated clinical guidelines for stem cell transplants in follicular lymphoma. These guidelines provide new recommendations on hematopoietic cell transplantation and cellular therapies, marking a significant advancement in treatment protocols. Key Highlights: 🔹 Autologous-HCT as an option for patients with disease progression within 24 months. 🔹 CAR-T therapy for those not achieving CR or PR after multiple lines of therapy. 🔹 Allogeneic-HCT for select relapsed chemosensitive patients post CAR-T failure. Dive into the detailed guidelines and download the PDF here: https://lnkd.in/e5N445ww Stay informed and keep up with the latest in lymphoma research! #lymsm #lymphomacoalition

COLUMVI SIGNIFICANTLY EXTENDS SURVIVAL IN PEOPLE WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA Roche announces their results from a Phase III STARGLO study of Columvi in combination with gemcitabine and oxaliplatin versus MabThera/Rituxan in combination with GemOx for people with relapsed or refractory (R/R) diffuse large B-cell lymphoma who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant, or who have received two or more prior lines of therapy. READ MORE... https://lnkd.in/eQrVHUC9

Genecast, we are committed to keeping you updated with the latest developments in oncology involving novel biomarkers and targeted treatments. Today, We brought two updates to keep you informed: 🧬JAK2 V617F Mutation Detection: A recent study underscores the importance of sensitive molecular detection of the JAK2 V617F mutation as a predictor of relapse in myelofibrosis (MF) patients post-allogeneic stem cell transplantation (alloSCT). By tracking the variant allele frequency (VAF) of this mutation, we can better assess relapse risks and improve patient outcomes. 🧬Niraparib for ccRCC Patients: Another development involves the use of niraparib, a PARP inhibitor, which has shown effectiveness in treating a 50-year-old patient with clear cell renal cell carcinoma (ccRCC) possessing mutations in the HRR pathway genes. This suggests that niraparib could be a promising targeted treatment option for similar patients. Check the comments for full articles. #Biomarkers #JAK2V617F #ccRCC #TargetedTherapy #LiquidBiopsy #CancerDiagnosis #CancerDetection #PrecisionMedicine #Genecast #ADPS

Reposting Ulrike Köhl Fischer, L., Grieb, N., Born, P. et al. Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma. Leukemia (2024). https://lnkd.in/dutCJ3xm "Abstract B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T cells revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM). However, data on cellular (CAR) T cell dynamics and the association with response, resistance or the occurrence of cytokine release syndrome (CRS) are limited. Therefore, we performed a comprehensive flow cytometry analysis of 27 RRMM patients treated with Idecabtagene vicleucel (Ide-cel) to assess the expansion capacity, persistence and effects on bystander cells of BCMA-targeting CAR T cells. Additionally, we addressed side effects, like cytokine release syndrome (CRS) and cytopenia. Our results show that in vivo expansion of CD8+ CAR T cells is correlated to response, however persistence is not essential for durable remission in RRMM patients. In addition, our data provide evidence, that an increased fraction of CD8+ T cells at day of leukapheresis in combination with successful lymphodepletion positively influence the outcome. We show that patients at risk for higher-grade CRS can be identified already prior to lymphodepletion. Our extensive characterization contributes to a better understanding of the dynamics and effects of BCMA-targeting CAR T cells, in order to predict the response of individual patients as well as side effects, which can be counteracted at an early stage or even prevented." https://lnkd.in/dT_gzYiD

An important and insightful study looking into potential predictors of CAR-T treatment outcomes based on pretreatment T cell analysis. While we aspire to bring transformative therapies to patients, deepening our understanding of the underlying success mechanisms at work is key. Screening patients for the highest likelihood of response to CAR-T therapy could significantly validate patient access policy and enable more targeted treatment options for predicted non-responders. The study also provides important validation of preserving T cell stemness to maximise the potential for treatment success. Excited to see more research of this kind.

📄 [Press release] – MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT 🩸 Key highlights: ✅ DSMB recommends proceeding as planned without modifications ✅ MaaT033 has shown to have an acceptable safety profile and was well tolerated in patients treated for blood cancers and receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). 🦠Phase 2b trial PHOEBUS, the largest one to date for a microbiome therapy in oncology, is an international, multi-center, randomized, double-blind, testing MaaT033, an oral freeze-dried formulation against placebo. https://lnkd.in/emffi3dR #Microbiome #BloodCancer #Cancer #DSMB #Safety

🥼 🔬 🧪 Paper of the Day ❗ ❗ ❗ MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial In this research article Andrés et al.2021 discussed a results of a clinical trial phase 2 of MATRix _ RICE therapy and autologous haematopoietic stem-cell transplantation for the of secondary CNS lymphoma. MATRix-RICE, investigates the effectiveness of a combined therapy for patients with diffuse large B-cell lymphoma (DLBCL) that has spread to the central nervous system (CNS). The therapy involves a unique regimen of radiation therapy, chemotherapy, and autologous hematopoietic stem cell transplantation (HSCT). #Cancer #Oncology #Cancerbiology #lymphoma #stemcells #Researcharticle #Openaccess #SOL #Scienceoflives #Scienceoflife #Biology #Chemistry #Biologicalprocess link to today's paper - https://lnkd.in/gN6ESmmN Date: 08/10/2024 For more, click the link below https://lnkd.in/gmJuz4eC